Tuberculosis in the 21st century: An emerging pandemic?

Norsk Epidemiologi

Volumn 15, Issue 2, 2005, Pages 133-139

  Bjune, Gunnar ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BCG VACCINATION; DISEASE TRANSMISSION; EARLY DIAGNOSIS; EUROPE; HOST PARASITE INTERACTION; HUMAN; MICROSCOPY; MYCOBACTERIUM TUBERCULOSIS; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SPUTUM ANALYSIS; SPUTUM SMEAR; TUBERCULOSIS;

EID: 32044466038     PISSN: 08032491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Dubos R, Dubos J. The white Plague: Tuberculosis, man, and society. Rutgers University Press, 1987, New Brunswick, Boston.
2. Raviglione MC, Sudre P, Rieder HL, Spinaci S, Kochi A. Secular trends of tuberculosis in western Europe. Bull World Health Org 1993; 71: 297.
3. Narain JP, Raviglione MC, Kochi A. HIV-associated tuberculosis in developing countries:epidemiology and strategies for prevention. Tuber Lung Dis 1992; 71: 311.
4. Snider D. TB: the world situation. History of the disease and efforts to combat it. John Wiley, New York.
5. Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ 1994; 72: 213.
6. Schulzer M, Fitzgerald JM, Enarson DA, Grzybowski S. An estimate of the future size of the tuberculous problem in Sub-saharan Africa resulting from HIV infection. Tuber Lung Dis 1992; 73: 52-58.
7. Kuemmerer JM, Comstock GW. Sociologic concomitants of tuberculin sensitivity: Am Rev Respir Dis 96: 885-892.
8. Grzybowski S, Enarson D. Results in pulmonary tuberculosis patients under various treaatment program conditions. Bull Int Union Tuberc 1978; 53: 70.
9. Marshall SH. DNA shuffling: induced molecular breeding to produce new generation long lasting vaccines. Biotech Adv 2002; 20: 229-238.
10. Rad ME, Bifani P, Martin C, Kremer K, Samper S, Rauzier J, et al. Mutations in putative mutator genes of Mycobacterium tuberculosis strains of the W-Beijing family. Emerg Infect Dis 2003; 9: 838-845.
11. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 1991; 72: 1-6.
12. Enarson DA, Grzybowski S. Incidence of active tuberculosis in the native population of Canada. Can Med Assoc J 1986; 134: 677-686.
13. Toungoussova OS, Mariandyshev A, Bjune G, Sandven P, Caugant DA. Molecular epidemiology and drug resistance of Mycobacterium tuberculosis isolates in the Archangel prison in Russia: predominance of the Beijing clone family. Clin Infect Dis 2003; 37: 665-672.
14. Toungoussova OS, Caugant DA, Sandven P, Mariandyshev AO, Nizovtseva NI, Bjune G. Spread of drug resistant Mycobacterium tuberculosis strains of the Beijing genotype in the Archangel Oblast, Russia. J Clin Microbiol 2002; 40: 1930-1937.
15. Glynn JR, Whitley J, Bifani BJ, Kremer K, van Sooligan D. World wide occurrence of Beijing/Wstrains of Mycobacterium tuberculosis: a systematic review. Emerg Infect Dis 2002; 8: 843-849.
16. Caminero JA, Pena MJ, Campos-Herrero MI, Rodriguez JC, Garcia I, Cabrera T, et al. Epidemiological evidence of the spread of a Mycobacterium tuberculosis strain of the Beijing genotype on Gran Canaria Island. Am J Respir Crit Care Med 2001; 164: 1165-1170.
17. Toungoussova OS, Caugant DA, Sandven P, Mariandyshev AO, Bjune G. Impact of drug resistance on fitness of Mycobacterium tuberculosis strains of the Beijing genotype. FEMS Immunol Med Microbiol 2004; 42: 281-290.
18. WHO. Drug resistant tuberculosis levels ten times higher in Eastern Europe and Central Asia. http://www.who.int/mediacentre/releases/2004/pr17/en/.
19. Anh DD, Borgdorff MW, Van LN, Lan NT, van Gorkom T, Kremer K, van Soolingen D. Mycobacterium tuberculosis Beijing genotype emerging in Vietnam. Emerg Infect Dis 2000; 6: 302-305.
20. Lopez B, Aguilar D, Orozco H, Burger M, Espitia C, Ritacco V, et al. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin Exp Immunol 2003; 133: 3037.
21. Van Rie A, Victor TC, Richardson M, Johnson R, van der Spuy GD, Murray EJ, et al. Re-infection and mixed infections cause changing Mycobacterium tuberculosis drug-resistance patterns. Am J Respir Crit Care Med 2005; 172: 636-642.
22. Mustafa T, Mogga SJ, Mfhanga SG, Morkve O, Sviland L. Significance of Fas and Fas ligand in tuberculous lymphadenetis. Immunol 2005; 114: 255-262.
23. Mustafa T, Phyu S, Nilsen R, Jonsson R, Bjune G. A mouse model for slowly progressive primary tuberculosis. Scand J Immunol 1999; 50: 127-136.
24. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 515-516.
25. Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR, et al. Massive gene decay in the leprosy bacillus. Nature 2001; 409: 1007-1011.
26. Abebe F, Mustafa T, Nerland AH, Bjune GA. Cytokine profile during latent and slowly progressive primary tuberculosis: a possible role for interleukin-15 in mediating clinical disease. Clin Exp Immunol 2006; 143: 180-192.
27. Sherman LF, Fujiwara PI, Cook SV, Bazerman LB, Frieden TR. Patient and health care system delays in the diagnosis of and treatment of tuberculosis. Int J Tuberc Lung Dis 1999; 3: 1088-1095.
28. El-sony A, Enarson D, Khamis A, Baraka O, Bjune G. Relations of grading of sputum smears with clinical features of tuberculosis in patients in routine practice in Sudan. Int J Tuberc Lung Dis 2002; 6: 91-97.
29. Yimer S, Bjune G, Alene G. Diagnostic and treatment delay among pulmonary tuberculosis patients in Ethiopia: a cross sectional study. BMC Infect Dis 2005; 5: 112.